CBD Reprograms Immune Cells to Be More Anti-Inflammatory, but Only When They Are Activated | Research

The takeaway

CBD reprogrammed human dendritic cells during long-term treatment to produce a more anti-inflammatory response when activated, including more IL-10 production and reduced ability to activate T cells, but had no effect on resting cells.

Immunology researchers, autoimmune disease specialists, CBD researchers.

CBD reprogrammed immune cells for anti-inflammatory response only when activated, not at rest

What the researchers found

CBD during differentiation had no acute effect on resting dendritic cells, but when subsequently activated by LPS (bacterial signal), CBD-treated cells showed a markedly tolerogenic response: more IL-6, TNFa, and importantly IL-10 (anti-inflammatory), with IL-10 signaling being the most prominently induced pathway. CBD-treated cells were less efficient at activating naive T cells. Effects were consistent across TLR4 and TLR7/8 stimulation.

Why it matters

This explains a puzzle about CBD and inflammation: CBD does not simply suppress immune cells but reprograms them to respond differently when challenged. This has implications for autoimmune conditions where you want to reduce inflammatory responses without completely suppressing immunity.

The numbers in context

CBD up to 10 uM. IL-10 signaling most prominently induced pathway in activated CBD-treated cells. Reduced T cell activation. Consistent across TLR4 and TLR7/8 stimulation. CBN and THCV had no measurable effects.

How the study worked

In vitro study using human monocyte-derived dendritic cells treated with CBD (up to 10 uM) during differentiation, then activated with TLR agonists. Assessed viability, differentiation markers, maturation markers, cytokine production, T cell activation, and transcriptome via Reactome pathway analysis.

What this study cannot tell us

In vitro study with human cells but not in vivo. Concentrations used may not reflect achievable tissue levels. Only tested CBD; other cannabinoids (CBN, THCV) had no effect. Long-term treatment required for reprogramming.

How to read the evidence

Well-designed in vitro study with multiple activation pathways and transcriptomic analysis, but limited to cell culture.

When this study was published

Published 2023.

The bigger picture

This "conditional" anti-inflammatory mechanism is therapeutically attractive. Unlike broad immunosuppression, CBD-reprogrammed dendritic cells would still function normally until activated, then shift toward tolerance. This could explain why CBD shows anti-inflammatory effects in disease models but not in healthy subjects.

Questions still open

Does this dendritic cell reprogramming occur in vivo at achievable CBD doses?
Could CBD-treated dendritic cells be used as a cellular therapy for autoimmune conditions?

Common questions

How does CBD affect the immune system?

This study found CBD reprograms dendritic cells during long-term exposure to produce more anti-inflammatory signals (especially IL-10) when activated, but has no effect on resting cells.

Could CBD help with autoimmune diseases?

The conditional anti-inflammatory reprogramming found in this study is promising for autoimmune conditions, but these are cell culture results that need to be confirmed in vivo.

Read the original research

The dual role of cannabidiol on monocyte-derived dendritic cell differentiation and maturation.

Frontiers in immunology, 14, 1240800

View on PubMed ↗Publisher’s paper ↗

Citation

Pénzes, Zsófia; Alimohammadi, Shahrzad; Horváth, Dorottya; Oláh, Attila; Tóth, Balázs István; Bácsi, Attila; Szöllősi, Attila Gábor. (2023). The dual role of cannabidiol on monocyte-derived dendritic cell differentiation and maturation.. Frontiers in immunology, 14, 1240800. https://doi.org/10.3389/fimmu.2023.1240800